Rakovina Therapeutics Congratulates Scientific Advisor Dr. Artem Cherkasov on Global Recognition for Breakthrough AI Innovation in Drug Discovery

Article content

VANCOUVER, British Columbia, April 22, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to congratulate its Scientific Advisor and collaborator, Dr. Artem Cherkasov, on his recent global recognition as a leader in AI-driven therapeutic development.

Article content

Article content

Dr. Cherkasov, a professor at the University of British Columbia and a principal investigator with the Vancouver Prostate Centre, was recently featured by the Vancouver Coastal Health Research Institute (VCHRI) in an article titled “AI innovation puts VCHRI scientist at forefront of global drug discovery avenues.” The feature highlights his groundbreaking contributions to the use of artificial intelligence in computational drug modeling and the development of the Deep Docking™ platform—an AI engine capable of screening billions of molecules to identify the most promising drug candidates with speed and precision.

Article content

Article content

As a key scientific advisor to Rakovina Therapeutics, Dr. Cherkasov plays an integral role in guiding the company’s AI-driven discovery efforts. Rakovina holds exclusive access to the Deep Docking™ platform for the development of novel DNA-damage response (DDR) inhibitors—an approach designed to accelerate therapeutic discovery and improve treatment outcomes for cancers with limited options.

Article content

Article content

“Dr. Cherkasov’s global recognition is a well-earned reflection of his pioneering spirit and the transformative power of AI in oncology drug development,” said Jeffrey Bacha, executive chairman of Rakovina Therapeutics. “Our collaboration with Dr. Cherkasov allows us to integrate cutting-edge AI into our discovery engine, positioning Rakovina at the forefront of innovation in targeted cancer therapy.”

Article content

Rakovina Therapeutics remains committed to leveraging world-class science and technology to develop new treatments for patients with difficult-to-treat cancers. The company is proud to partner with Dr. Cherkasov in this mission.

Article content

About Rakovina Therapeutics Inc.

Article content

Article content

Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking™ and Enki™ platforms. By using AI, we can review and optimize drug candidates at a much greater pace than ever before.

Article content

The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners.

Article content

Article content

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Article content

Notice Regarding Rakovina Therapeutics Forward-Looking Statements:

Article content

This release includes forward-looking statements regarding the company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans,” “is expected,” “expects,” “scheduled,” “intends,” “contemplates,” “anticipates,” “believes,” “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results “may,” “could,” “would,” “might,” or “will” be taken, occur, or be achieved. Such statements are based on the current expectations of the management of the company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition.